Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 5Phase 1/2 4Phase NA 1Phase 4 1Phase 3 1

Status

Recruiting 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Neoplasms 27Colorectal Neoplasms 26Neoplasm Metastasis 24Recurrence 22Ovarian Neoplasms 22Pancreatic Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Prostatic Neoplasms 18Melanoma 17Glioblastoma 15Lymphoma, Large B-Cell, Diffuse 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 13Endometrial Neoplasms 13Multiple Myeloma 12Lung Neoplasms 12Colonic Neoplasms 12Triple Negative Breast Neoplasms 11Carcinoma, Renal Cell 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Glioma 10Gastrointestinal Neoplasms 10Rectal Neoplasms 9Lymphoma, Follicular 9Lymphoma 9Head and Neck Neoplasms 8Burkitt Lymphoma 8

Interventions

Temozolomide 2Bevacizumab 2trastuzumab deruxtecan 1Radiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Astrocytoma × 30 days × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01269853 2026-06-01

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Northwell Health

Phase 1/2 Recruiting
54 enrolled
CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT01386710 2026-06-01

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Northwell Health

Phase 1/2 Suspended
54 enrolled
CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT05765812 2026-05-28

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Debiopharm International SA

Phase 1/2 Recruiting
116 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡